[Collagen diseases and rheumatic diseases].
Takeuchi
Tsutomu
T
Amano
Koichi
K
Tsuzake
Kensei
K
Kameda
Hideto
H
Abe
Toru
T
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid; D015551:Autoimmunity; D004359:Drug Therapy, Combination; D019676:Genes, T-Cell Receptor delta; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D000069285:Infliximab; D007555:Isoxazoles / Q000494:pharmacology / Q000627:therapeutic use; D000077339:Leflunomide; D008180:Lupus Erythematosus, Systemic / Q000453:epidemiology / Q000209:etiology / Q000628:therapy; D008214:Lymphocytes / Q000276:immunology; D008727:Methotrexate / Q000627:therapeutic use; D011239:Prednisolone / Q000008:administration & dosage; D011379:Prognosis; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology
D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D007166:Immunosuppressive Agents; D007555:Isoxazoles; D014409:Tumor Necrosis Factor-alpha; D011239:Prednisolone; D000069285:Infliximab; D000077339:Leflunomide; D008727:Methotrexate